Abstract: A method for manufacturing a detector of a first and a second incident ionizing radiation including determining the abscissa em of a point of intersection between a first and a second curve, with the first and second curves representing the evolution of the number of photons or electrical charges generated per second by a transducing material as a function of the total thickness of an amplifying material when the transducing material is irradiated, through this thickness of transducing material, by the first and second incident ionizing radiation, respectively; then selecting the total thickness of amplifying material between 0.9 em and 1.1 em and producing the detector with the selected thickness of amplifying material.

Abstract: The present disclosure relates to methods for treating infectious disorders. In particular, the disclosure provides BTN3A activating antibodies, and their use in treating infectious disorders in a human subject in need thereof, such as disorders caused by SARS-Cov2 or Coxiella burnetii infection.

Abstract: The invention relates to a device (2, 4) for homogenizing a radiofrequency field, for magnetic resonance imaging, of a given wavelength emitted by a volumetric antenna, comprising at least one continuous metal track (8) with a total length of between 50% and 75% of the wavelength of the radiofrequency field, the metal track comprising two end segments extending in mutually parallel directions and a main portion extending between the two end segments and comprising several local deformations identical to one another and connected to one another in series by at least one at least partially rectilinear connection portion (14) in such a way as to provide the homogenizing device (2, 4) with an electric dipole property, the homogenizing device having a fundamental frequency higher than the frequency corresponding to the wavelength of the radiofrequency field.

Abstract: The present invention relates to antibodies having specificity for BTN2A and uses thereof, in particular for the treatment of cancer.

Abstract: An etching method includes: a physical adsorption process of physically adsorbing an adsorbate based on a first processing gas on a film to be etched under a condition that the pressure of the first processing gas is smaller than the saturated vapor pressure of the first processing gas with respect to a temperature of an object to be processed while cooling the object to be processed on which the film to be etched is formed; and an etching process of etching the film to be etched by reacting the adsorbate with the film to be etched by a plasma of a second processing gas.

Abstract: It is disclosed anti-BTN3A activating antibody fragments that specifically bind to BTN3A and activate the cytolytic function of V?9/V?2 T cells. The disclosure more specifically relates to specific anti-BTN3A binding proteins comprising such activating antibody fragments and their use in the manufacturing of novel drugs for use in treating cancer disorders, in particular cancers susceptible to be treated with activated ?? T cells.

Abstract: The present invention pertains to the field of nanoimprint lithography (NIL) processes and more specifically to a soft NIL process used for providing a sol-gel patterned layer on a substrate. Specifically, this process comprises a step of adjusting the solvent uptake of the sol-gel film to 10 to 50% vol., preferably between 15 and 40% vol., by varying the relative pressure of the solvent while a soft mould is applied onto the substrate coated with the sol-gel film.

Abstract: The method of modulating epileptogenicity in a brain of an epileptic patient includes: providing a virtual brain; providing a model of an epileptogenic and of a propagation zones and loading the models in the virtual brain to create a virtual epileptic brain; acquiring data of the brain of the epileptic patient; identifying, in the data, a location of at least one possible epileptogenic zone; fitting the virtual epileptic brain against the data acquired from the epileptic patient and parametrizing the at least one possible epileptogenic zone in the virtual epileptic brain as an epileptogenic zone; and simulating, within the virtual epileptic brain, the effect of a network modulation mimicking a clinical intervention of the brain of the patient.

Abstract: The present invention relates to antimicrobial peptides, variants and chemical analogues thereof; in particular, a peptide of 20 amino acids, named Michelicin, having the sequence RVCVRICRNGRCYRRCWNT, derived from a longer precursor with a BRICHOS domain from the marine worm Capitella. The peptide has several cysteines which form disulfide bridges and provide stability in salt conditions. Several derivatives and analogues were produced. The peptide and the derivatives show antimicrobial activity against a wide range of bacteria. The application also concerns nucleic acid sequences encoding these, pharmaceutical composition and to their use as a drug, preservative and disinfectant.

Abstract: The invention relates to a material for use as a pad in high field and/or very high field magnetic resonance imaging instrument, comprising at least one polar solvent having a melting point of 14° C. to 50° C., a dispersant and a dielectric charge. The invention relates also to a pad used in field of high field and/or very high field magnetic resonance imaging made of at least such a material.

Abstract: A solid organic material comprising at least one amphiphilic block copolymer of the methacrylic type, the block copolymer being dispersed in a polymer matrix, the block copolymer having a number-average molar mass (Mn) greater than or equal to 20 000 g/mol; a method for preparing said solid organic material; use of said solid organic material for antibacterial, antimicrobial, antiviral, anti-inflammatory and/or antifungal applications; a coating comprising said solid organic material.

Abstract: The present invention concerns a method for electrochemically depolluting an aqueous solution containing at least one heavy metal, said method comprising the following steps: a) a step of measuring the pH of the aqueous solution, optionally followed by a step of adapting said pH by adding a strong acid or a strong base, b) bringing said aqueous solution into contact with a reference electrode, a counter-electrode and a working electrode comprising a conductive substrate, c) applying a constant potential to the arrangement, as a result of which a film of at least one heavy metal oxide is formed on said working electrode, this step being capable of being repeated when the aqueous solution contains several heavy metals, and d) recovering a depolluted aqueous solution and said film.

Abstract: The method of simulating a human brain neural field in a computerized platform modelling various zones of a human brain and connectivity between the zones includes: providing the computerized platform modelling the various zones of the human brain and connectivity between the zones; acquiring three-dimensional anatomical structural imaging data of a folded surface of a cortex of a brain of a human patient; personalizing the computerized platform according to the structural data; providing an equation describing a spatiotemporal evolution of the neural field and loading the equation in the computerized platform; performing a projection of the surface of the cortex of the brain of the patient on a spherical surface domain; simulating the neural field in the spherical domain; and translating the simulated neural field in the spherical domain in the cortical domain.

Abstract: The present invention concerns clusterin for use in the treatment of thrombotic microangiopathies, and a pharmaceutical composition comprising clusterin for use in the treatment of thrombotic microangiopathies, said composition not comprising von Willebrand factor protease. The present invention also concerns an ex vivo method for stratifying a patient suffering, or likely to be suffering, from TMA, comprising the following steps: 1) measuring, in a biological sample from said patient, the amount LC of clusterin, and 2) comparing the amount Lc measured in step 1) with an amount Lref of clusterin by calculating the score S1=LC/Lref, in which: •If S1?1, the patient is considered to be likely to benefit from a treatment of the TMA with clusterin, •If S1>1, the patient is not considered to be likely to benefit from treatment of TMA with clusterin.

Abstract: A method for identifying a microorganism to be identified, which includes the following steps: obtaining an Excitation-Emission EEM of the microorganism to be identified, analysing the main components of the EEM matrix using at least one reference EEMr matrix, projecting the result of the analysis onto a plane defined by two main components, and identifying the microorganism to be identified.

Abstract: The present invention relates to hybrid transcription regulatory elements to drive gene expression, in particular hybrid promoters, designed by the fusion of at least two transcription regulatory elements with different tissue selectivity, such as two promoters driving expression in different tissues in a tissue-selective manner.

Abstract: The present invention relates to an optically pure (+) or (?) enantiomer of a ruthenium complex having formula (I) as well as the preparation method of said enantiomer, and uses thereof as catalyst, in particular in asymmetric olefin metathesis.

Abstract: The deep brain stimulation system has at least four stimulation pairs of electrodes. Each stimulation pair of electrodes provides an electric stimulation at a carrier frequency. The mean value between the carrier frequency of any first stimulation pair of electrodes and the carrier frequency of any second stimulation pair of electrodes defines a first mean carrier frequency. The mean value between the carrier frequency of any third stimulation pair of electrodes and the carrier frequency of any fourth stimulation pair of electrodes defines a second mean carrier frequency. The difference between the first and second mean carrier frequencies is equal to or greater than 200 Hz.

Abstract: A phytopharmaceutical method for treating a plant organ affected by a phytopathogenic fungal strain. The method includes the steps of applying on the plant organ a composition including at least one xanthone UPR (Unfolded Protein Response) inhibitor, preferably, an IRE-1 (Inositol-Requiring Enzyme 1) inhibitor, in a sub-effective amount. Also, a phytopharmaceutical composition including at least one UPR (Unfolded Protein Response) inhibitor in a sub-effective amount.

Abstract: The invention relates to Variable Domain of Camelid Heavy Chain-only (VHH) molecules which bind TfR and the uses thereof e.g., to transport molecules of pharmaceutical or diagnostic interest into cells and in organs, in pathological conditions including cancer.